Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction.

[1]  H. Schunkert,et al.  Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease: Results From the ISAR-TEST 4 Randomized Trial , 2019, Circulation.

[2]  Volkmar Falk,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.

[3]  G. Hindricks,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[4]  M. Togni,et al.  Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent). , 2017, JACC. Cardiovascular interventions.

[5]  J. Southard,et al.  Very late stent thrombosis with second generation drug eluting stents compared to bare metal stents: Network meta‐analysis of randomized primary percutaneous coronary intervention trials , 2016, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[6]  Kristian Thorlund,et al.  The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations , 2015, Annals of Internal Medicine.

[7]  P. Serruys,et al.  Biolimus-eluting stent with biodegradable polymer improves clinical outcomes in patients with acute myocardial infarction , 2014, Heart.

[8]  Anna Chaimani,et al.  Evaluating the Quality of Evidence from a Network Meta-Analysis , 2014, PloS one.

[9]  L. Räber,et al.  Biolimus-Eluting Stents With Biodegradable Polymer Versus Bare-Metal Stents in Acute Myocardial Infarction: Two-Year Clinical Results of the COMFORTABLE AMI Trial , 2014, Circulation. Cardiovascular interventions.

[10]  G. Stone,et al.  Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. , 2014, Journal of the American College of Cardiology.

[11]  E. Tuzcu,et al.  Stent Thrombosis With Second-Generation Drug-Eluting Stents Compared With Bare-Metal Stents: Network Meta-Analysis of Primary Percutaneous Coronary Intervention Trials in ST-Segment–Elevation Myocardial Infarction , 2014, Circulation. Cardiovascular interventions.

[12]  Mario Fusaro,et al.  Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis , 2013, BMJ.

[13]  G. Stone,et al.  Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. , 2013, Journal of the American College of Cardiology.

[14]  M. Togni,et al.  Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial , 2013, The Lancet.

[15]  C. Terkelsen,et al.  Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial , 2013, The Lancet.

[16]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[17]  Gerta Rücker,et al.  Network meta‐analysis, electrical networks and graph theory , 2012, Research synthesis methods.

[18]  G. Stone,et al.  Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. , 2012, Archives of internal medicine.

[19]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[20]  L. Räber,et al.  Current status of drug-eluting stents. , 2011, Cardiovascular therapeutics.

[21]  Neil Hawkins,et al.  Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: A tutorial , 2010, BMC medical research methodology.

[22]  P. Serruys,et al.  Incomplete stent apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction than in drug-eluting stents implanted for stable/unstable angina: insights from optical coherenc , 2009, JACC. Cardiovascular interventions.

[23]  P. Serruys,et al.  Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Long-Term Outcome After Bare Metal and Drug-Eluting Stent Implantation , 2008, Circulation. Cardiovascular interventions.

[24]  P. Serruys,et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.

[25]  L. Stewart,et al.  To IPD or not to IPD? , 2002, Evaluation & the health professions.

[26]  P. Serruys,et al.  Does angiography six months after coronary intervention influence management and outcome? Benestent II Investigators. , 1999, Journal of the American College of Cardiology.

[27]  L. Stewart,et al.  Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. , 2015, JAMA.

[28]  B. Brodie,et al.  Very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction: a 15-year single-center experience. , 2011, JACC. Cardiovascular interventions.

[29]  F. Eberli,et al.  Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease Final 5-Year Report (Limus Eluted From A Durable Versus ERodable Stent Coating) Randomi , 2022 .